Source comparison
TB-500 Wound Healing Complete Guide 2026: Comparison Table
Acute surgical incision (< 10cm) 2–5mg Twice weekly × 3 weeks 10–14 days (vs 18–21 untreated) Accelerated keratinocyte migration, reduced inflammatory phase duration Standard protocol. Well-supported in rodent models, human data emerging Chronic diabetic ulcer
This comparison does not assign a generated winner or score.
- Acute surgical incision (< 10cm)
- 2–5mg
- Twice weekly × 3 weeks
- 10–14 days (vs 18–21 untreated)
- Accelerated keratinocyte migration, reduced inflammatory phase duration
- Standard protocol. Well-supported in rodent models, human data emerging
- Chronic diabetic ulcer (> 6 weeks non-healing)
- 7.5–10mg
- Three times weekly × 6 weeks
- 4–8 weeks (variable based on vascular status)
- VEGF upregulation, MMP-9 normalization, improved angiogenesis in hypoxic tissue
- Requires concurrent glycemic control. TB-500 alone insufficient if HbA1c > 9%
- Tendon or ligament tear (partial thickness)
- 5–7.5mg
- Twice weekly × 8 weeks
- 6–10 weeks to functional load tolerance
- Collagen type I deposition, reduced myofibroblast differentiation, preserved elasticity
- Longer protocol necessary. Tendon remodeling phase extends 12+ weeks
- Second-degree burn (> 15% TBSA)
- 10mg
- Three times weekly × 4 weeks
- 14–21 days to re-epithelialization
- Enhanced keratinocyte proliferation, reduced hypertrophic scar formation
- High-dose justified by surface area. Monitor for fluid shifts during acute phase